DNTH — Dianthus Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.45bn
- $4.04bn
- $2.04m
Annual cashflow statement for Dianthus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -71.1 | -76.5 | -43.6 | -85 | -162 |
| Depreciation | |||||
| Non-Cash Items | 11.1 | 10.1 | 1.76 | 7.04 | 16.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.53 | -2.7 | 4.86 | -0.351 | 16.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -59.5 | -67.1 | -36.9 | -78.2 | -129 |
| Capital Expenditures | -1.26 | -0.314 | -0.11 | -0.105 | -0.213 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 44.7 | -9.5 | 20.4 | -287 | -123 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 43.4 | -9.81 | 20.3 | -287 | -123 |
| Financing Cash Flow Items | 86.1 | -0.141 | 134 | 215 | -0.364 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 89.6 | 2.88 | 134 | 256 | 280 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 73.5 | -74 | 117 | -109 | 28.2 |